S
14.77
-0.09 (-0.61%)
| Previous Close | 14.86 |
| Open | 14.97 |
| Volume | 1,411,144 |
| Avg. Volume (3M) | 1,123,906 |
| Market Cap | 1,431,827,456 |
| Price / Sales | 545.94 |
| Price / Book | 7.01 |
| 52 Weeks Range | |
| Earnings Date | 7 Nov 2024 - 11 Nov 2024 |
| Operating Margin (TTM) | -1,051.64% |
| Diluted EPS (TTM) | -0.500 |
| Quarterly Revenue Growth (YOY) | 4,900.00% |
| Total Debt/Equity (MRQ) | 0.05% |
| Current Ratio (MRQ) | 12.56 |
| Operating Cash Flow (TTM) | -45.86 M |
| Levered Free Cash Flow (TTM) | -31.67 M |
| Return on Assets (TTM) | -16.22% |
| Return on Equity (TTM) | -22.41% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | ARS Pharmaceuticals, Inc. | Bullish | Bullish |
AIStockmoo Score
-1.4
| Analyst Consensus | 3.0 |
| Insider Activity | -5.0 |
| Price Volatility | -4.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | -1.40 |
|
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 23.16% |
| % Held by Institutions | 68.11% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 30.00 (Cantor Fitzgerald, 103.11%) | Buy |
| Median | 27.50 (86.19%) | |
| Low | 25.00 (Leerink Partners, 69.26%) | Buy |
| Average | 27.50 (86.19%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 14.33 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Cantor Fitzgerald | 08 Oct 2024 | 30.00 (103.11%) | Buy | 13.88 |
| 16 Sep 2024 | 30.00 (103.11%) | Buy | 12.95 | |
| Leerink Partners | 20 Sep 2024 | 25.00 (69.26%) | Buy | 14.77 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| CHAKMA JUSTIN | - | 14.20 | -100,000 | -1,419,343 |
| Aggregate Net Quantity | -100,000 | |||
| Aggregate Net Value ($) | -1,419,343 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 14.20 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| CHAKMA JUSTIN | Officer | 27 Nov 2024 | Sell (-) | 25,000 | 14.53 | 363,250 |
| CHAKMA JUSTIN | Officer | 26 Nov 2024 | Sell (-) | 42,186 | 14.37 | 606,213 |
| CHAKMA JUSTIN | Officer | 25 Nov 2024 | Sell (-) | 32,814 | 13.71 | 449,880 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |